Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 22 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT02848651Phase 2Results posted
• Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung CancerTerminatedNCT02846792Phase 1/2Results posted
• Improving Pulmonary Function Following Radiation TherapyCompletedNCT02843568Not applicableResults posted
• Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790MCompletedNCT02841579Phase 2Results posted
• FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung CancerCompletedNCT02839265Phase 2Results posted
• Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)CompletedNCT02835690Phase 1Results posted
• A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid TumorsTerminatedNCT02834247Phase 1Results posted
• Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal MelanomaTerminatedNCT02831933Phase 2Results posted
• A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung CancerTerminatedNCT02826161Phase 3Results posted
• TG4010 and Nivolumab in Patients With Lung CancerCompletedNCT02823990Phase 2Results posted
• Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission TomographyCompletedNCT02819024Not applicableResults posted
• Neoadjuvant PembrolizumabCompletedNCT02818920Phase 2Results posted
• Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung CancerCompletedNCT02810457Phase 3Results posted
• Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results posted
• PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung CancerCompletedNCT02793856Phase 1Results posted
• A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung CancerCompletedNCT02789345Phase 1Results posted
• A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)CompletedNCT02775435Phase 3Results posted
• A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02774278Phase 2Results posted
• FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT ImagingCompletedNCT02773238Phase 2Results posted
• Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02771626Phase 1/2Results posted
• Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung CancerTerminatedNCT02770014Phase 2Results posted
• Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLCTerminatedNCT02768558Phase 3Results posted
• Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung CancerTerminatedNCT02762877Results posted
• A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung CancerCompletedNCT02754882Phase 3Results posted
• Real World Data on Gi(l)Otrif® Dose AdjustmentCompletedNCT02751879Results posted
• Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung CancerTerminatedNCT02751385Phase 1Results posted
• An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT02750514Phase 2Results posted
• ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT02737501Phase 3Results posted
• Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2CompletedNCT02733159Phase 2Results posted
• Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT02730247Phase 2Results posted
• S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)CompletedNCT02728596Not applicableResults posted
• Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung CancerCompletedNCT02718066Phase 1/2Results posted
• Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLCCompletedNCT02716038Phase 2Results posted
• Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor CancerCompletedNCT02713529Phase 1/2Results posted
• A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.TerminatedNCT02711345Phase 1Results posted
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
• Genetic Predictors of Benefit to PembrolizumabTerminatedNCT02710396Phase 2Results posted
• Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsTerminatedNCT02706626Phase 2Results posted
• Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ MalignanciesTerminatedNCT02706392Phase 1Results posted
• Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet ChemotherapyCompletedNCT02705820Phase 2Results posted
• Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) LobectomiesCompletedNCT02702921Not applicableResults posted
• Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)TerminatedNCT02695290Phase 4Results posted
• Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxelCompletedNCT02684461Phase 2Results posted
• Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)CompletedNCT02681549Phase 2Results posted
• Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)CompletedNCT02679170Results posted
• LUME BioNIS: a Biomarker Study in Patients With NSCLCCompletedNCT02671422Results posted
• MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived TumorsTerminatedNCT02669914Phase 2Results posted
• Nintedanib and Weekly Docetaxel in Lung AdenocarcinomaCompletedNCT02668393Phase 1Results posted
• Exemestane in Post-Menopausal Women With NSCLCCompletedNCT02666105Phase 2Results posted
• Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE TrialCompletedNCT02664181Phase 2Results posted
• Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung CancerCompletedNCT02659059Phase 2Results posted
• An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadCompletedNCT02658890Phase 1/2Results posted
• A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)CompletedNCT02657434Phase 3Results posted
• OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor FailureTerminatedNCT02654587Phase 3Results posted
• Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung CancerActive, not recruitingNCT02642042Phase 2Results posted
• Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT02638090Phase 1/2Results posted
• A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLCTerminatedNCT02630186Phase 1/2Results posted
• Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung CancerCompletedNCT02621398Phase 1Results posted
• Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal MetastasesCompletedNCT02616393Phase 2Results posted
• Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT02613507Phase 3Results posted
• Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and CrizotinibCompletedNCT02604342Phase 3Results posted
• 18F-FSPG PET/CT for Cancer Patients on TherapyCompletedNCT02599194Phase 2Results posted
• Afatinib in NSCLC With HER2 MutationCompletedNCT02597946Phase 2Results posted
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results posted
• A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung CancerCompletedNCT02595450Results posted
• Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLCCompletedNCT02591615Phase 2Results posted
• Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung CancerTerminatedNCT02590003Phase 2Results posted
• Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine TumorsActive, not recruitingNCT02589522Phase 1Results posted
• Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02588612Phase 1Results posted
• A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsTerminatedNCT02588261Phase 3Results posted
• Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)TerminatedNCT02584634Phase 1/2Results posted
• Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung CancerCompletedNCT02581943Phase 2Results posted
• SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung CancerCompletedNCT02581787Phase 1/2Results posted
• Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)CompletedNCT02578680Phase 3Results posted
• Avelumab in First-line NSCLC (JAVELIN Lung 100)CompletedNCT02576574Phase 3Results posted
• MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer PatientsCompletedNCT02574598Phase 2Results posted
• A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results posted
• Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)CompletedNCT02572843Phase 2Results posted
• BIO 300 Non-Small Cell Lung Cancer StudyCompletedNCT02567799Phase 1/2Results posted
• Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02546986Phase 2Results posted
• Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in METCompletedNCT02544633Phase 2Results posted
• Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerCompletedNCT02535338Phase 1/2Results posted
• Phase I, Study in Chinese NSCLC PatientsCompletedNCT02529995Phase 1Results posted
• ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT02523469Phase 1/2Results posted
• Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung CancerTerminatedNCT02521051Phase 1/2Results posted
• Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or OlderCompletedNCT02514174Phase 4Results posted
• Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer PatientsTerminatedNCT02511184Phase 1Results posted
• A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02507375Phase 1Results posted
• Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLCCompletedNCT02504489Phase 3Results posted
• Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)CompletedNCT02504372Phase 3Results posted
• A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsActive, not recruitingNCT02498613Phase 2Results posted
• A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02495233Phase 1/2Results posted
• A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung CancerCompletedNCT02492867Not applicableResults posted
• RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)CompletedNCT02489903Phase 2Results posted
• Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersCompletedNCT02487095Phase 1/2Results posted
• Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]CompletedNCT02486718Phase 3Results posted
• Evaluation of the Impact of Nurse-led Telephone on Treatment ComplianceTerminatedNCT02483416Results posted
• An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02477826Phase 3Results posted
• Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory CancerCompletedNCT02475213Phase 1Results posted
• Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic DiseaseTerminatedNCT02469701Phase 2Results posted

← Carcinoma, Non-Small-Cell Lung overview